286
Participants
Start Date
October 31, 2009
Study Completion Date
December 31, 2010
Saxagliptin
5 mg, oral tablet, once daily
Metformin
500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
Research Site, Brussels (woluwe-st-lambert)
Research Site, Halen
Research Site, Lommel
Research Site, Oostham
Research Site, Sint-Gillis-Waas
Research Site, Zoersel
Research Site, Bruges
Research Site, Moerkerke
Research Site, Tielt
Research Site, Châtellerault
Research Site, Corbeil-Essonnes
Research Site, La Rochelle
Research Site, La Seyne-sur-Mer
Research Site, Paris
Research Site, Seysses
Research Site, Tiercé
Research Site, Berlin
Research Site, Freiburg im Breisgau
Research Site, Leipzig
Research Site, Ludwigshafen
Research Site, Mannheim
Research Site, Rhaunen
Research Site, Schmiedeberg
Research Site, Wahlstedt
Research Site, Bergamo
Research Site, Forlì
Research Site, Milan
Research Site, Padua
Research Site, Pordenone
Research Site, Siena
Research Site, Roma
Research Site, Seville
Research Site, Barcelona
Research Site, A Coruña
Research Site, Madrid
Research Site, San Sebastián de los Reyes
Research Site, Oviedo
Research Site, Alicante
Research Site, Ankara
Research Site, Bursa
Research Site, Kırıkkale
Research Site, Ankara
Research Site, Reading
Research Site, Atherstone
Research Site, Royal Leamington Spa
Research Site, Warminster
Research Site, Westbury
Research Site, Ashford
Research Site, Bath
Research Site, Coventry
Research Site, Peterborough
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
AstraZeneca
INDUSTRY